Medine Cumhur Cüre1, Erkan Cüre2, Yıldıray Kalkan3, Aynur Kırbaş1, Levent Tümkaya3, Arif Yılmaz4, Ayşegül Küçükali Türkyılmaz5, İbrahim Şehitoğlu6, Süleyman Yüce7. 1. Department of Biochemistry, Recep Tayyip Erdoğan University School of Medicine, Rize, Turkey. 2. Department of Internal Medicine, Recep Tayyip Erdoğan University School of Medicine, Rize, Turkey. 3. Department of Histology and Embryology, Recep Tayyip Erdoğan University School of Medicine, Rize, Turkey. 4. Department of Gastroenterology, Recep Tayyip Erdoğan University School of Medicine, Rize, Turkey. 5. Department of Physical Medicine and Rehabilitation, Recep Tayyip Erdoğan University School of Medicine, Rize, Turkey. 6. Department of Pathology, Recep Tayyip Erdoğan University School of Medicine, Rize, Turkey. 7. Department of Internal Medicine, Kumru State Hospital, Rize, Turkey.
Abstract
BACKGROUND: Cisplatin (Cis) is one of the most commonly used antineoplastic drugs. It is used as chemotherapy for many solid organ malignancies such as brain, neck, male and female urogenital, vesical and pulmonary cancers. Infliximab blocks tumor necrosis factor alpha (TNF-α). Several studies have reported that infliximab ameliorates cell damage by reducing cytokine levels. AIMS: We aimed to investigate whether infliximab has a preventive effect against cisplatin-induced hepatotoxicity and whether it has a synergistic effect when combined with Cis. STUDY DESIGN: Animal experimentation. METHODS: Male Wistar albino rats were divided in three groups as follows: Cis group, infliximab + Cis (CIN) group and the control group. Each group comprised 10 animals. Animals in the Cis group received an intraperitoneal single-dose injection of Cis (7 mg/kg). In the CIN group, a single dose of infliximab (7 mg/kg) was administered 72 h prior to the Cis injection. After 72 h, a single dose of Cis (7 mg/kg) was administered. All rats were sacrificed five days after Cis injection. RESULTS: TNF-α levels in the Cis group were significantly higher (345.5±40.0 pg/mg protein) than those of the control (278.7±62.1 pg/mg protein, p=0.003) and CIN groups (239.0±64.2 pg/mg protein, p=0.013). The Cis group was found to have high carbonic anhydrase (CA)-II and low carbamoyl phosphate synthetase-1 (CPS-1) levels. Aspartate transaminase (AST) and alanine transaminase (ALT) levels were lower in the CIN group as compared to the Cis group. Total histological damage was greater in the Cis group as compared to the control and CIN groups. CONCLUSION: Cis may lead to liver damage by increasing cytokine levels. It may increase oxidative stress-induced tissue damage by increasing carbonic anhydrase II (CA-II) enzyme levels and decreasing CPS-1 enzyme levels. Infliximab decreases Cis-induced hepatic damage by blocking TNF-α and it may also protect against liver damage by regulating CPS-1 and CA-II enzyme levels.
BACKGROUND:Cisplatin (Cis) is one of the most commonly used antineoplastic drugs. It is used as chemotherapy for many solid organ malignancies such as brain, neck, male and female urogenital, vesical and pulmonary cancers. Infliximab blocks tumor necrosis factor alpha (TNF-α). Several studies have reported that infliximab ameliorates cell damage by reducing cytokine levels. AIMS: We aimed to investigate whether infliximab has a preventive effect against cisplatin-induced hepatotoxicity and whether it has a synergistic effect when combined with Cis. STUDY DESIGN: Animal experimentation. METHODS: Male Wistar albino rats were divided in three groups as follows: Cis group, infliximab + Cis (CIN) group and the control group. Each group comprised 10 animals. Animals in the Cis group received an intraperitoneal single-dose injection of Cis (7 mg/kg). In the CIN group, a single dose of infliximab (7 mg/kg) was administered 72 h prior to the Cis injection. After 72 h, a single dose of Cis (7 mg/kg) was administered. All rats were sacrificed five days after Cis injection. RESULTS: TNF-α levels in the Cis group were significantly higher (345.5±40.0 pg/mg protein) than those of the control (278.7±62.1 pg/mg protein, p=0.003) and CIN groups (239.0±64.2 pg/mg protein, p=0.013). The Cis group was found to have high carbonic anhydrase (CA)-II and low carbamoyl phosphate synthetase-1 (CPS-1) levels. Aspartate transaminase (AST) and alanine transaminase (ALT) levels were lower in the CIN group as compared to the Cis group. Total histological damage was greater in the Cis group as compared to the control and CIN groups. CONCLUSION: Cis may lead to liver damage by increasing cytokine levels. It may increase oxidative stress-induced tissue damage by increasing carbonic anhydrase II (CA-II) enzyme levels and decreasing CPS-1 enzyme levels. Infliximab decreases Cis-induced hepatic damage by blocking TNF-α and it may also protect against liver damage by regulating CPS-1 and CA-II enzyme levels.
Authors: Gul N Shah; Timothy S Rubbelke; Joshua Hendin; Hien Nguyen; Abdul Waheed; James D Shoemaker; William S Sly Journal: Proc Natl Acad Sci U S A Date: 2013-04-15 Impact factor: 11.205
Authors: Carmen Diez-Fernandez; Ana I Martínez; Satu Pekkala; Belén Barcelona; Isabel Pérez-Arellano; Ana María Guadalajara; Marshall Summar; Javier Cervera; Vicente Rubio Journal: Hum Mutat Date: 2013-05-28 Impact factor: 4.878
Authors: Alice Santi; Anna Caselli; Paolo Paoli; Denise Corti; Guido Camici; Giuseppe Pieraccini; Maria Letizia Taddei; Sergio Serni; Paola Chiarugi; Paolo Cirri Journal: Cell Commun Signal Date: 2013-10-29 Impact factor: 5.712
Authors: Sameh S Elhady; Reda F A Abdelhameed; Eman T Mehanna; Alaa Samir Wahba; Mahmoud A Elfaky; Abdulrahman E Koshak; Ahmad O Noor; Hanin A Bogari; Rania T Malatani; Marwa S Goda Journal: Antioxidants (Basel) Date: 2022-04-22
Authors: Mostafa M El-Sheekh; Mohamed Nassef; Eman Bases; Shimaa El Shafay; Rania El-Shenody Journal: Cancer Cell Int Date: 2022-08-23 Impact factor: 6.429